Oral Solid Dosage Contract Manufacturing Market size is valued at USD 22,678.1 million in 2021 and expected to grow at a significant CAGR of 6.4% during the forecast period 2022 to 2028. The global market provides a detailed overview and that can be segmented by product type, by release mechanism, and end user. By product type, the market has been segmented into Tablets, Capsules, Powders & Granules (MT). The Tablets segment is likely to be the largest and fastest-growing segment in terms of product type. Based By release mechanism, the market is segmented into Tablets (Immediate Release, Modified Release, Chewable Tablets, and Effervescent Tablets. Capsules (Controlled Release, Enteric Release, and Others), Powders & Granules (Uncoated Powders & Granules, Coated Granules). The tablets segment is expected to dominate the oral solid dosage contract manufacturing market. Based on the end user, the market has been segregated into Big Pharma or Biotech, Small & Medium Size Pharma or Biotech, Emerging or Virtual Pharma, and Nutraceutical Companies. The Big Pharma or Biotech segment is expected to dominate other segments in the Oral Solid Dosage Contract Manufacturing market according to Precision Business Insights.
In September 2018, Aurobindo acquired the dermatology and oral solids businesses from Sandoz Inc. This will support Sandoz’s strategy of focusing on complex generics, value-added medicines, and biosimilars to achieve sustainable and profitable growth in the U.S. over the long term.